Hope › Vision 2030

The Road to $65 Billion

India’s pharmaceutical exports crossed $31 billion in FY2025–26. The official industry roadmap — presented by Commerce Minister Piyush Goyal and developed by Bain & Company with Pharmexcil — targets $65 billion in pharma exports by 2030.

$31B

FY26 exports
(actual)

$65B

2030 export
target

$130B

2030 total sector
(domestic + export)

$350B

2047 export
aspiration

Where the Target Comes From

The $65 billion export target was presented in “Healing the World: A Roadmap for Making India a Global Pharma Exports Hub,” a report developed by Bain & Company in partnership with the Pharmaceuticals Export Promotion Council (Pharmexcil). It was unveiled by Commerce Minister Piyush Goyal at IDMA’s 63rd Annual Day.

The broader $130 billion figure for the total pharmaceutical sector (domestic + exports combined) by 2030 comes from the Department of Pharmaceuticals, as reported by DD News. Looking further ahead, IBEF cites a $350 billion export aspiration by 2047 — India’s centenary year.

The Math: Is $65 Billion Achievable?

From $31 billion in FY26 to $65 billion by 2030 requires a compound annual growth rate of approximately 20%. For context, India’s pharma export CAGR over the past twelve years (FY15–FY26) was approximately 7.5%.

Reaching $65 billion would require the industry to more than double its current trajectory. That is ambitious. But the Bain/Pharmexcil roadmap identifies specific growth levers — not a linear extrapolation of past performance.

Evidence check

phrma.in presents the $65B target as stated by its source (Bain/Pharmexcil). The required CAGR (~20%) substantially exceeds the historical rate (~7.5%). Whether the identified growth levers can close that gap is a matter of execution, not data — and this site does not make forward projections.

Five Growth Levers

The Bain/Pharmexcil roadmap identifies specific sectors where export growth is expected to accelerate. These are not predictions by phrma.in — they are the strategic categories identified in the official roadmap.

1. Complex Generics and Biosimilars

Moving beyond simple generics to complex formulations (injectables, inhalers, transdermals, peptides) and biosimilars, where margins are higher and competition is thinner. India’s first wave of biosimilars — led by Biocon, Dr. Reddy’s, and Cipla — is already in regulated markets.

2. Contract Development and Manufacturing (CDMO)

Global pharmaceutical companies are increasingly outsourcing manufacturing to India. The CDMO opportunity leverages India’s existing manufacturing infrastructure, quality certifications, and cost advantage to serve as a production partner rather than a generic competitor.

3. API Self-Sufficiency and Export

India currently imports approximately 68% of its Active Pharmaceutical Ingredients from China. The government’s Bulk Drug Parks scheme and PLI (Production Linked Incentive) programme aim to build domestic API capacity — first reducing import dependency, then converting API manufacturing into an export category.

4. New Market Penetration

Expanding from established markets (US, UK, South Africa) into underpenetrated regions — Latin America, Central Europe, Southeast Asia, and the Middle East. phrma.in’s country profiles show the current distribution; the growth opportunity lies in markets where India’s share is still small.

5. Digital Health and MedTech

Adjacent sectors — medical devices, diagnostics, digital therapeutics — represent new export categories. India’s medical devices exports, though small today, are growing rapidly and are targeted for acceleration under the same industrial policy framework.

The Journey So Far

Twelve years of pharmaceutical export data, from $14 billion to $31 billion. Each milestone based on DGCIS actual trade data as reported on the phrma.in homepage.

FY 2014–15 $14.0 billion — the baseline year on phrma.in’s trend chart
FY 2017–18 $17.3 billion — steady growth through GST transition
FY 2020–21 $24.4 billion — pandemic-driven surge in demand
FY 2023–24 $27.9 billion — post-pandemic normalisation
FY 2024–25 $30.5 billion — crossing the $30 billion threshold
FY 2025–26 $31+ billion — current year (DGCIS preliminary)
2030 Target $65 billion — Bain/Pharmexcil export roadmap

Sources: $65B export target: Bain & Company, “Healing the World: A Roadmap for Making India a Global Pharma Exports Hub,” presented by Commerce Minister Piyush Goyal at IDMA’s 63rd Annual Day. $130B sector target: DD News / Department of Pharmaceuticals. $350B by 2047: IBEF. FY26 exports ($31B+): DrugsControl.org citing Pharmexcil Handbook. FY25 exports ($30.47B): Pharmexcil Handbook (9.4% YoY growth). Historical export data (FY15–FY25): DGCIS India, as used throughout phrma.in.